^
Association details:
| Biomarker: | miR-21 underexpression |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IMATINIB RESPONSE AND MICRORNAS PROFILE IN CML – A BIOMARKER FOR DRUG RESPONSE
Published date:
05/17/2018
Excerpt:
…patients with miR-451 expression levels higher than 5.69 and lower expression levels of miR-21 than 1.16x10-4 have an optimal response to Imatinib at 12 months [AUC 0.77 (CI95% 0.58-0.95); Sensibility=92%; Specificity=64%; p=0,017; AUC 0.77 (CI95% 0.57-0.97); Sensibility=55%; Specificity=100%; p=0,021, respectively].
